Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of duchenne muscular dystrophy

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 508-515

  Peterson, Jennifer M ^a   Kline, William ^a   Canan, Benjamin D ^a   Ricca, Daniel J ^b   Kaspar, Brian ^c   Delfín, Dawn A ^a   Dirienzo, Kelly ^a   Clemens, Paula R ^d,e   Robbins, Paul D ^d   Baldwin, Albert S ^b   Flood, Pat ^b   Kaumaya, Pravin ^a   Freitas, Michael ^a   Kornegay, Joe N ^f   Mendell, Jerry R ^c   Rafael Fortney, Jill A ^a   Guttridge, Denis C ^a   Janssen, Paul Ml ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEMO BINDING DOMAIN PEPTIDE; SYNTHETIC PEPTIDE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM INJURY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DUCHENNE MUSCULAR DYSTROPHY; HISTOPATHOLOGY; MOUSE; MUSCLE SPASM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANIMALS; DIAPHRAGM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; MALE; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B; PEPTIDES;

EID: 79955417598     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00263     Document Type: Article

References (41)

1. Blake DJ, Weir A, Newey SE, Davies KE. (2002) Function and genetics of dystrophin and dys-trophin-related proteins in muscle. Physiol. Rev. 82:291-329.
2. Acharyya S, et al. (2007) Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117:889-901.
3. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. (2003) Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 60:993-997.
4. Chen YW, et al. (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 65:826-834.
5. Messina S, et al. (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am. J. Pathol. 168:918-926.
6. Messina S, et al. (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp. Neurol. 198:234-241.
7. Mendell JR, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med. 320:1592-1597.
8. De Bosscher K, et al. (1997) Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. U.S.A. 94:13504-13509.
9. De Bosscher K, et al. (2000) Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. U.S.A. 97:3919-3924.
10. Karin M, Ben-Neriah Y. (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18:621-663.
11. Perkins ND. (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell. Biol. 8:49-62.
12. Hayden MS, Ghosh S. (2008) Shared principles in NF-kappaB signaling. Cell. 132:344-362.
13. Baima ET, et al. (2010) Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides. J. Biol. Chem. 285:13498-13506.
14. Akers WS, Cross A, Speth R, Dwoskin LP, Cassis LA. (2000) Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 279:H2797-H2806.
15. Archer JD, Vargas CC, Anderson JE. (2006) Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. Faseb. J. 20:738-740.
16. Barton ER, Morris L, Kawana M, Bish LT, Toursel T. (2005) Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve. 32:751-760.
17. Carlson CG, Samadi A, Siegel A. (2005) Chronic treatment with agents that stabilize cytosolic IkappaB-alpha enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. Neuro-biol. Dis. 20:719-730.
18. Hnia K, et al. (2008) L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172:1509-1519.
19. Pan Y, et al. (2008) Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol. Cells. 25:531-537.
20. Siegel AL, et al. (2009) Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul. Disord. 19:131-139.
21. Voisin V, et al. (2005) L-arginine improves dys-trophic phenotype in mdx mice. Neurobiol. Dis. 20:123-130.
22. Stedman HH, et al. (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 352:536-539.
23. May MJ, et al. (2000) Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 289:1550-1554.
24. Mulieri LA, Hasenfuss G, Ittleman F, Blanchard EM, Alpert NR. (1989) Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. Circ. Res. 65:1441-1449.
25. Chandrasekharan K, et al. (2010) A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci. Transl. Med. 2:42ra54.
26. Janssen PML, Hiranandani N, Mays TA, Rafael-Fortney JA. (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dys-trophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 289:H2373-H2378.
27. Diaz PT, Brownstein E, Clanton TL. (1994) Effects of N-acetylcysteine on in vitro diaphragm function are temperature dependent. J. Appl. Physiol. 77:2434-2439.
28. Prezant DJ, et al. (1990) Temperature dependence of rat diaphragm muscle contractility and fatigue. J. Appl. Physiol. 69:1740-1745.
29. Rucker M, et al. (2004) Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development. 131:3007-3019.
30. Acharyya S, et al. (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 8:421-432.
31. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. (1999) NF-kappaB controls cell growth and differentiation through transcrip-tional regulation of cyclin D1. Mol. Cell. Biol. 19:5785-5799.
32. Chapoval SP, et al. (2007) Inhibition of NF-kappaB activation reduces the tissue effects of transgenic IL-13. J. Immunol. 179:7030-7041.
33. Dasgupta S, et al. (2004) Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J. Immunol. 173:1344-1354.
34. di Meglio P, Ianaro A, Ghosh S. (2005) Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum. 52:951-958.
35. Ghosh A, et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neu-ronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 104:18754-18759.
36. Shibata W, et al. (2007) Cutting edge: The Ikap-paB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 179:2681-2685.
37. Tas SW, et al. (2006) Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res. Ther. 8:R86.
38. Hayden MS, Ghosh S. (2004) Signaling to NF-kappaB. Genes. Dev. 18:2195-2224.
39. Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. (2006) Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteo-clastogenesis and calvarial inflammatory osteoly-sis. J. Orthop. Res. 24:1358-1365.
40. Dai S, Hirayama T, Abbas S, Abu-Amer Y. (2004) The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogene-sis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279:37219-37222.
41. Jimi E, et al. (2004) Selective inhibition of NF- kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10:617-624.